Evidence map›Paper›PMID 37503601›Full record

ArticleCirculation. Heart failure2023

Trends and Outcomes of Cardiogenic Shock in Patients With End-Stage Renal Disease: Insights From USRDS Database.

Tarun Dalia, Suveenkrishna Pothuru, Wan-Chi Chan, Harsh Mehta, Amandeep Goyal, Hassan Farhoud, Ilham Boda, Anureet Malhotra, Andrija Vidic, Aniket S Rali and 4 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Circulation. Heart failure, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Kidney Failure in Cardiogenic Shock.Circulation. Heart failure · 2026
    Review
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Tarun Dalia *Department of Cardiovascular Medicine, University of Kansas Health System (T.D., S.P., W.-C.C., H.M., A.G., A.V., K.G., Z.S.).ORCID 0000-0002-4115-6189
Suveenkrishna Pothuru *Department of Cardiovascular Medicine, University of Kansas Health System (T.D., S.P., W.-C.C., H.M., A.G., A.V., K.G., Z.S.).ORCID 0000-0002-4060-9561
Wan-Chi ChanDepartment of Cardiovascular Medicine, University of Kansas Health System (T.D., S.P., W.-C.C., H.M., A.G., A.V., K.G., Z.S.).ORCID 0000-0001-6883-5686
Harsh MehtaDepartment of Cardiovascular Medicine, University of Kansas Health System (T.D., S.P., W.-C.C., H.M., A.G., A.V., K.G., Z.S.).ORCID 0000-0002-2136-4183
Amandeep GoyalDepartment of Cardiovascular Medicine, University of Kansas Health System (T.D., S.P., W.-C.C., H.M., A.G., A.V., K.G., Z.S.).ORCID 0000-0001-6070-1747
Hassan FarhoudMedical Student, Class of 2023, University of Kansas Medical Center (H.F.).ORCID 0000-0001-8340-2571
Ilham BodaDepartment of Internal Medicine, University of Kansas Health System (I.B., A.M.).
Anureet MalhotraDepartment of Internal Medicine, University of Kansas Health System (I.B., A.M.).
Andrija VidicDepartment of Cardiovascular Medicine, University of Kansas Health System (T.D., S.P., W.-C.C., H.M., A.G., A.V., K.G., Z.S.).
Aniket S RaliDivision of Cardiovascular Medicine, Vanderbilt University Medical Center, Nashville, TN (A.S.R.).
Thomas C HanffDivision of Cardiovascular Medicine, University of Utah Health, Salt Lake City (T.C.H., J.C.F.).ORCID 0000-0003-3096-1227
Kamal GuptaDepartment of Cardiovascular Medicine, University of Kansas Health System (T.D., S.P., W.-C.C., H.M., A.G., A.V., K.G., Z.S.).ORCID 0000-0002-2440-9033
James C FangDivision of Cardiovascular Medicine, University of Utah Health, Salt Lake City (T.C.H., J.C.F.).ORCID 0000-0003-2427-9504
Zubair ShahDepartment of Cardiovascular Medicine, University of Kansas Health System (T.D., S.P., W.-C.C., H.M., A.G., A.V., K.G., Z.S.).ORCID 0000-0002-3221-3655

Funding

NHLBI NIH HHS L30 HL170339
6 · The paper itself

Abstract

backgroundThere is a paucity of data regarding epidemiology, temporal trends, and outcomes of patients with cardiogenic shock (CS) and end-stage renal disease (chronic kidney disease stage V on hemodialysis).

methodsThis is a retrospective cohort study using the United States Renal Data System database from January 1, 2006 to December 31, 2019. We analyzed trends of CS, percutaneous mechanical support (intraaortic balloon pump, percutaneous ventricular assist device [Impella and Tandemheart], and extracorporeal membrane oxygenation) utilization, index mortality, 30-day mortality, and 1-year all-cause mortality in end-stage renal disease patients.

resultsA total of 43 825 end-stage renal disease patients were hospitalized with CS (median age, 67.8 years [IQR, 59.4-75.8] and 59.1% men). From 2006 to 2019, the incidence of CS increased from 275 to 578 per 100 000 patients (

conclusionsThe incidence of CS in end-stage renal disease patients has doubled without significant change in the trend of index mortality despite the use of percutaneous mechanical support.

Indexed as

Heart-Assist DevicesHeart FailureKidney Failure, ChronicAgedFemaleHumansIntra-Aortic Balloon PumpingMaleRetrospective StudiesShock, CardiogenicTreatment OutcomeUnited Statesdialysisextracorporeal membrane oxygenationincidencerisk factorshock, cardiogenic

Identifiers

PMID37503601
PMCPMC11270562

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.